Johnson Pharmacare (532154) Q4 17/18 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 17/18 earnings summary
14 Oct, 2026Executive summary
No business activity was carried out in FY2017-18; operating revenue was nil and administrative costs resulted in a net loss of Rs. 624,712.
Working-capital scarcity continued to prevent operations; management pursued cost reductions and was seeking an opportunity to restart activity.
Financial highlights
FY2017-18 revenue was nil, versus Rs. 468,750 in FY2016-17; total expenses were Rs. 624,712 versus Rs. 1,221,519.
Net loss narrowed to Rs. 624,712 from Rs. 752,769; basic and diluted EPS improved to (Rs. 0.01) from (Rs. 0.02).
Total assets were Rs. 599.41 million at March 31, 2018, including investments of Rs. 540.34 million; total equity was Rs. 582.26 million.
Outlook and guidance
Future development depends on restarting operations; management was pursuing cost-reduction measures and evaluating opportunities to make operations functional.
Latest events from Johnson Pharmacare
- Working-capital constraints and share-sale losses accompanied a Rs 129.14 lakh FY23 net loss.532154
Q4 22/23 - A small profit returned, but working-capital scarcity kept operations largely dormant.532154Q4 20/21
- Rs 32.63m revenue and Rs 0.97m profit, but scarce working capital constrained operations.532154Q4 21/22
- No operations, zero revenue and a Rs 918,050 loss amid working-capital constraints.532154Q4 19/20
- A smaller loss offered little relief as working-capital scarcity kept operations inactive.532154Q4 18/19
- Inactive operations and working-capital scarcity drove a ₹752,769 FY17 loss.532154Q4 16/17
- No revenue, a ₹1.26 million loss, and scarce working capital stalled operations.532154Q4 15/16
- Inactive operations, nil FY15 revenue and a Rs 737,735 net loss amid funding constraints.532154Q4 14/15
- Revenue reached ₹17.91bn, but losses, cash burn and a debt repayment default persisted.532154Q4 13/14